Pooled Analysis from MagnetisMM Studies

Thomas G. Martin, MD, reviews findings from a pooled analysis from MagnetisMM that evaluated elranatamab in patients with relapsed/refractory MM who received prior BCMA-directed therapies.

EP: 1.Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma

EP: 2.Treatment Options in Late-line R/R MM Patients

EP: 3.Sequencing Options of Bispecifics in R/R MM

Now Viewing

EP: 4.Pooled Analysis from MagnetisMM Studies

EP: 5.Consideration in Treatment Selection and Sequencing in R/R MM

EP: 6.Clinical Scenario 2: A 70-Year-Old Male with R/R MM

EP: 7.Treatment Options for Late-line R/R MM

EP: 8.Overview of CAR-T Sequencing Strategies in R/R MM

EP: 9.Challenges in Optimizing Sequencing

EP: 10.Future Clinical Trials: Sequencing Decisions for Bispecifics and CAR T-Cell Therapy

EP: 11.Challenges in Optimizing Sequencing Strategies in R/R MM

EP: 12.Unmet Needs and Future Perspectives in Treatment Sequencing Strategies in R/R MM

Recent Videos